The study demonstrated a clear overall survival benefit for patients receiving maintenance therapy compared to a placebo.

One critical finding was an increased risk of developing a second primary malignancy (SPM) while on long-term lenalidomide maintenance. Patient Considerations

The (often referred to simply as the IFM-05 study) focused on using lenalidomide as a maintenance treatment.

If you are looking for guidance based on this study's results:

To determine if continuous low-dose chemotherapy after a transplant could improve overall survival and keep the disease controlled for longer periods.